Colon Cancer Stage III Clinical Trial
— CCXOfficial title:
The Effects of Chiropractic Care on the Quality of Life and Autonomic Nervous System in Adults With Colon Cancer: a Single-arm Pilot Trial
NCT number | NCT05310565 |
Other study ID # | I-0019 |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | January 1, 2025 |
Est. completion date | March 1, 2025 |
Verified date | April 2024 |
Source | Life University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main objectives of this single-arm pilot trial are to investigate the feasibility of our protocol in terms of 1) recruitment, 2) adherence, 3) tolerability, 4) acceptability and 5) retention. We aim to recruit 20 participants with advanced colon cancer (stage 3-4) who will have assessments of their autonomic nervous system function, carcinoembryonic antigen (CEA) levels, and patient-reported outcomes. Thereafter, patients will be directed to a nearby field clinic to receive twice-weekly cervical assessments & high-velocity, low-amplitude (HVLA) cervical adjustments for a period of 6 weeks. Re-assessments will be performed following 2 weeks and 6 weeks of chiropractic care.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | March 1, 2025 |
Est. primary completion date | March 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Males & females 18 years of age or older - Able to provide informed consent - Diagnosed with stage 3 or stage 4 colon cancer and currently receiving standard of care with a medical doctor. Exclusion Criteria: - Individuals with a known disorder resulting in syncope/fainting during postural changes (e.g., POTS, orthostatic hypotension) - Cancer has metastasized to the cervical spine - Individuals who have had a serious injury or surgery to the head, torso, lower body within the past 6 months. - Individuals with evidence or medical history of clinically significant psychiatric disorder like anti-social disorder, schizophrenia, or borderline personality disorder that is uncontrolled or untreated. - Individuals who currently have pending health related legal litigation. - Individuals with a known heart condition (e.g., arrhythmia) that could result in an aberrant electrocardiogram. - Individuals with a pacemaker - Individuals who are on short benzodiazepines which include midazolam & triazolam - Individuals with conditions that could result in neck instability such as rheumatoid arthritis. - Individuals who do not present with a subluxation in the upper cervical region (C1/C2) at any point during the 6 weeks of chiropractic care. - Individuals with a condition that may cause weak or brittle bones such as osteoporosis - Since x-rays may be requested for care, participants who are pregnant will be excluded from the study. |
Country | Name | City | State |
---|---|---|---|
United States | Dr. Sid E. Williams Center for Chiropractic Research | Atlanta | Georgia |
Lead Sponsor | Collaborator |
---|---|
Life University | University of Haifa |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recruitment rate | Length of time needed to recruit target number of participants | Upon reaching target number of completed participant trials | |
Primary | Patient adherence rate | Proportion of participants able to adhere to the testing & treatment protocol/schedule | Upon reaching target number of completed participant trials | |
Primary | Patient tolerability rate | Proportion of participants able to perform all aspects of the testing regimen | Upon reaching target number of completed participant trials | |
Primary | Acceptability of treatment regimen to participants | 8-item Theoretical Framework of Acceptability questionnaire | Week 6 | |
Primary | Patient Retention | Proportion of enrolled participants who complete the full trial | Upon reaching target number of completed participant trials | |
Secondary | Electrodermal activity (EDA) skin conductance level (SCL) | 2 sensors on first and second digits of non-dominant hand | Day 1 | |
Secondary | Electrodermal activity (EDA) skin conductance level (SCL) | 2 sensors on first and second digits of non-dominant hand | Week 2 | |
Secondary | Electrodermal activity (EDA) skin conductance level (SCL) | 2 sensors on first and second digits of non-dominant hand | Week 6 | |
Secondary | Electrodermal activity (EDA) power spectral density (PSD) | 2 sensors on first and second digits of non-dominant hand | Day 1 | |
Secondary | Electrodermal activity (EDA) power spectral density (PSD) | 2 sensors on first and second digits of non-dominant hand | Week 2 | |
Secondary | Electrodermal activity (EDA) power spectral density (PSD) | 2 sensors on first and second digits of non-dominant hand | Week 6 | |
Secondary | Electrodermal activity (EDA) non-specific skin conductance responses (SCR) | 2 sensors on first and second digits of non-dominant hand | Day 1 | |
Secondary | Electrodermal activity (EDA) non-specific skin conductance responses (SCR) | 2 sensors on first and second digits of non-dominant hand | Week 2 | |
Secondary | Electrodermal activity (EDA) non-specific skin conductance responses (SCR) | 2 sensors on first and second digits of non-dominant hand | Week 6 | |
Secondary | Impedance cardiogram (ICG) pre-ejection period (PEP) | 2 sensors on chest and 2 sensors on back | Day 1 | |
Secondary | Impedance cardiogram (ICG) pre-ejection period (PEP) | 2 sensors on chest and 2 sensors on back | Week 2 | |
Secondary | Impedance cardiogram (ICG) pre-ejection period (PEP) | 2 sensors on chest and 2 sensors on back | Week 6 | |
Secondary | Impedance cardiogram (ICG) initial systolic time interval (ISTI) | 2 sensors on chest and 2 sensors on back | Day 1 | |
Secondary | Impedance cardiogram (ICG) initial systolic time interval (ISTI) | 2 sensors on chest and 2 sensors on back | Week 2 | |
Secondary | Impedance cardiogram (ICG) initial systolic time interval (ISTI) | 2 sensors on chest and 2 sensors on back | Week 6 | |
Secondary | ECG interbeat interval | 3 sensors on torso | Day 1 | |
Secondary | ECG interbeat interval | 3 sensors on torso | Week 2 | |
Secondary | ECG interbeat interval | 3 sensors on torso | Week 6 | |
Secondary | ECG respiratory sinus arrhythmia (RSA) | 3 sensors on torso | Day 1 | |
Secondary | ECG respiratory sinus arrhythmia (RSA) | 3 sensors on torso | Week 2 | |
Secondary | ECG respiratory sinus arrhythmia (RSA) | 3 sensors on torso | Week 6 | |
Secondary | ECG de-trended fluctuation analysis | 3 sensors on torso | Day 1 | |
Secondary | ECG de-trended fluctuation analysis | 3 sensors on torso | Week 2 | |
Secondary | ECG de-trended fluctuation analysis | 3 sensors on torso | Week 6 | |
Secondary | Carcinoembryonic antigen (CEA) levels | Off-site blood draw and lab testing | Day 1 | |
Secondary | Carcinoembryonic antigen (CEA) levels | Off-site blood draw and lab testing | Week 6 | |
Secondary | Patient-reported outcomes | 5 questionnaires: EORTC QLQ-C30, COMPASS-31, PROMIS-29, PROMIS-Cog, Perceived Stress Scale | Day 0 | |
Secondary | Patient-reported outcomes | 5 questionnaires: EORTC QLQ-C30, COMPASS-31, PROMIS-29, PROMIS-Cog, Perceived Stress Scale | Day 1 | |
Secondary | Patient-reported outcomes | 5 questionnaires: EORTC QLQ-C30, COMPASS-31, PROMIS-29, PROMIS-Cog, Perceived Stress Scale | Week 2 | |
Secondary | Patient-reported outcomes | 5 questionnaires: EORTC QLQ-C30, COMPASS-31, PROMIS-29, PROMIS-Cog, Perceived Stress Scale | Week 6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
Completed |
NCT00309530 -
Randomized Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Colon Carcinoma Dukes C
|
Phase 3 | |
Completed |
NCT04342676 -
Lymph Node Ratio and Kras Mutation in R Colon Cancer
|
Phase 3 | |
Enrolling by invitation |
NCT05179889 -
Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer
|
Phase 2/Phase 3 | |
Withdrawn |
NCT05433402 -
Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06108310 -
ArTificial inTelligence-based RAdiogenomics in Colon Tumors
|
||
Not yet recruiting |
NCT04488159 -
Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer
|
Phase 3 | |
Recruiting |
NCT05194878 -
Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers
|
Phase 3 |